Kahira Pharmaceuticals and Chemical Industries Co
Kahira Pharmaceuticals maintains a conservative capital structure with a debt-to-equity ratio of 0.34, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 2.2, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow of EGP 247.36 million indicates strong cash generation, though capital expenditures of EGP 168.47 million suggest ongoing investment in infrastructure or production capacity. Profitability metrics show a return on equity of 9.47% and a return on assets of 4.82%, which are to be compared against industry benchmarks for pharmaceutical firms. These figures suggest Kahira is generating returns above the typical cost of capital, though the ROA is moderate, indicating room for improvement in asset utilization. Geographic and segment exposure is not explicitly detailed in the available data, but as a domestic Egyptian firm, Kahira's revenue is likely concentrated within the local market. The absence of international revenue breakdowns or segment-specific financials limits the ability to assess diversification risk. Growth trajectory is supported by a strong operating cash flow of EGP 119.40 million and a net income of EGP 74.55 million. However, the company's future growth will depend on its ability to maintain or expand its market share in a competitive domestic pharmaceutical landscape. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund new initiatives without external financing. No dilution risk is currently flagged, and no adjustments have been applied to the valuation metrics. Recent events or filings are not detailed in the provided data, but the company's financial health appears stable with no immediate signs of distress. Continued monitoring of capital expenditures and debt management will be important for assessing long-term sustainability.
Business. Kahira Pharmaceuticals and Chemical Industries Co is an Egyptian pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products.
Classification. Kahira is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.
- Kahira Pharmaceuticals maintains a conservative capital structure with a debt-to-equity ratio of 0.34.
- The company generates strong free cash flow of EGP 247.36 million, indicating robust operational performance.
- Return on equity of 9.47% suggests Kahira is generating returns above the typical cost of capital.
- The company's liquidity position is characterized as medium risk, with a current ratio of 2.2.
- Kahira's net cash position is negative after subtracting total debt, which could constrain its ability to fund new initiatives without external financing.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.